Status: technology licensed off Pyrosequencing AB developed the sequencing chemistry from which it took its name. In 2003 they acquired Biotage and changed their name to that of the acquired company. Biotage was later sold to Qiagen who has licensed the pyrosequencing technology exclusively to 454 (now Roche) for high density/high throughput sequencing applications. Please […]
Sequencing companies are born and sequencing companies die. Or get acquired. Or just change their names. We honor those that have come before us.
Status: no longer developing NGS platform Sequenom acquired IP relating to NGS from Harvard University (based on Amit Meller’s work) in 2007 with the aim of developing their own NGS-based diagnostic platform. In 2010 they returned the technology to Harvard. While Sequenom is using NGS technology in developing their diagnostic products, they no longer appear […]
Status: acquired Solexa developed a sequencer based on sequencing-by-synthesis and bridge amplification technology. In 2006, prior to full commercialization of the new system, they were acquired by Illumina. The Solexa technology forms the basis for all of Illumina’s sequencing systems to date. Please contact us at firstname.lastname@example.org if you have any information or opinions you’d […]
Status: ceased operations; technology acquired and shelved VisiGen was developing a single molecule sequencer when they were acquired by Life Technologies (Invitrogen) in 2008 for $20M. The technology, now known by the codename ‘Starlight’, has been deprioritized due to the focus on the SOLiD and Ion Torrent technologies. In a recent court filing in the […]
Status: ceased operations Xagros Genomics was formed in 2001 based on IP for charge detection during DNA synthesis from Ron Davis’ lab at Stanford. After the company folded in 2004, the IP reverted back to Stanford and was later acquired by Ion Torrent.